Market capitalization | $188.26m |
Enterprise Value | $-34.69m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.84 |
EV/Sales (TTM) EV/Sales | -0.43 |
P/S ratio (TTM) P/S ratio | 2.35 |
P/B ratio (TTM) P/B ratio | 0.62 |
Revenue growth (TTM) Revenue growth | -68.00% |
Revenue (TTM) Revenue | $80.00m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
12 Analysts have issued a Voyager Therapeutics, Inc. forecast:
12 Analysts have issued a Voyager Therapeutics, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 80 80 |
68%
68%
|
|
Gross Profit | 75 75 |
69%
69%
|
|
EBITDA | -79 -79 |
162%
162%
|
EBIT (Operating Income) EBIT | -83 -83 |
168%
168%
|
Net Profit | -65 -65 |
149%
149%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Alfred Sandrock |
Employees | 172 |
Founded | 2013 |
Website | www.voyagertherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.